DHRDanaher Corporation
Price
+13%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: the price
Quality mixed, no red flags, demanding price, growing in the filings, the market undecided.
Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. Danaher is comprised of more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors, organized under three segments (Biotechnology, Life Sciences and Diagnostics). United by the DANAHER BUSINESS SYSTEM (“DBS”), our businesses are also typically characterized by a high level of products and services that are sold on a recurring basis, primarily through a direct sales model and to a geographically diverse customer base.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Danaher Corporation (DHR) reported revenue of $6.26B in Q2 2026 (quarter ended Jun 26, 2026), up 5.5% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $870M (14% of revenue). For the full year FY2025, revenue was $24.6B (+2.9% year on year) and net income $3.61B. Its largest segment in Q2 2026 was Diagnostics at $1.13B, 46% of the disclosed total, ahead of Life Sciences at 31%. The next results filing is expected around Oct 20, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Appointment of Julie Sawyer Montgomery as President and Chief Executive Officer On August 3, 2026, Danaher Corporation (the “Company” or “Danaher”) announced that, effective as of October 1, 2026 (the “Effective Date”), the Board of Directors of the Company (the “Board”) has appointed Julie Sawyer Montgomery as …Director or officer change · Form 8-K
- Jul 21, 2026Innovation at the speed of life.Earnings release · press release
- Jun 3, 2026On June 3, 2026, Danaher Corporation, a Delaware corporation (the “Company”), and its wholly owned subsidiary DH Masi Finance Inc., a Delaware corporation (the “Issuer”), entered into a note purchase and guaranty agreement among the Company, the Issuer and the institutional accredited investors named therein (the …New debt or off-balance-sheet obligation · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $2.47BThe company’s own SEC segment disclosure.
- Diagnostics$1.13B46%
- Life Sciences$759.0M31%
- Biotechnology$583.0M24%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry